Literature DB >> 23402023

The effects of selective complement and CD14 inhibition on the E. coli-induced tissue factor mRNA upregulation, monocyte tissue factor expression, and tissue factor functional activity in human whole blood.

O L Brekke1, C Waage, D Christiansen, H Fure, H Qu, John D Lambris, B Østerud, E W Nielsen, T E Mollnes.   

Abstract

BACKGROUND: The complement pathway and CD14 play essential roles in inflammation, but little is known about the relative roles of complement and CD14 in E. coli-induced tissue factor (TF) mRNA upregulation, expression by monocytes, and functional activity in human whole blood.
METHODS: Whole E. coli bacteria were incubated for up to 4 h in human whole blood containing the anticoagulant lepirudin, which does not affect complement activation. TF mRNA levels were analyzed using reverse transcription, quantitative real-time PCR (RT-qPCR), and the expression of TF on the cell surface was analyzed using flow cytometry. Complement was selectively inhibited using the C3 convertase inhibitor compstatin or a C5a receptor antagonist (C5aRa), while CD14 was blocked by an anti-CD14 F(ab')2 monoclonal antibody.
RESULTS: The E. coli-induced TF mRNA upregulation was reduced to virtually background levels by compstatin, whereas anti-CD14 had no effect. Monocyte TF expression and TF activity in plasma microparticles were significantly reduced by C5aRa. Anti-CD14 alone only slightly reduced E. coli-induced monocyte TF expression but showed a modest additive effect when combined with the complement inhibitors. Inhibiting complement and CD14 efficiently reduced the expression of the E. coli-induced cytokines IL-1beta, IL-6, IL-8, and platelet-derived growth factor bb.
CONCLUSION: Our results indicate that E. coli-induced TF mRNA upregulation is mainly dependent on complement activation, while CDI4 plays a modest role in monocyte TF expression and the plasma TF activity in human whole blood.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23402023     DOI: 10.1007/978-1-4614-4118-2_8

Source DB:  PubMed          Journal:  Adv Exp Med Biol        ISSN: 0065-2598            Impact factor:   2.622


  12 in total

Review 1.  Clinical promise of next-generation complement therapeutics.

Authors:  Dimitrios C Mastellos; Daniel Ricklin; John D Lambris
Journal:  Nat Rev Drug Discov       Date:  2019-07-19       Impact factor: 84.694

2.  Complement Component C5 and TLR Molecule CD14 Mediate Heme-Induced Thromboinflammation in Human Blood.

Authors:  Anub M Thomas; Alexandra Gerogianni; Martin B McAdam; Yngvar Fløisand; Corinna Lau; Terje Espevik; Per H Nilsson; Tom Eirik Mollnes; Andreas Barratt-Due
Journal:  J Immunol       Date:  2019-08-14       Impact factor: 5.422

3.  Alginate microbeads are coagulation compatible, while alginate microcapsules activate coagulation secondary to complement or directly through FXII.

Authors:  Caroline Gravastrand; Shamal Hamad; Hilde Fure; Bjørg Steinkjer; Liv Ryan; Josè Oberholzer; John D Lambris; Igor Lacík; Tom Eirik Mollnes; Terje Espevik; Ole-Lars Brekke; Anne Mari Rokstad
Journal:  Acta Biomater       Date:  2017-05-30       Impact factor: 8.947

Review 4.  Compstatin: a C3-targeted complement inhibitor reaching its prime for bedside intervention.

Authors:  Dimitrios C Mastellos; Despina Yancopoulou; Petros Kokkinos; Markus Huber-Lang; George Hajishengallis; Ali R Biglarnia; Florea Lupu; Bo Nilsson; Antonio M Risitano; Daniel Ricklin; John D Lambris
Journal:  Eur J Clin Invest       Date:  2015-03-09       Impact factor: 4.686

5.  Chimeric anti-CD14 IGG2/4 Hybrid antibodies for therapeutic intervention in pig and human models of inflammation.

Authors:  Corinna Lau; Kristin S Gunnarsen; Lene S Høydahl; Jan Terje Andersen; Gøril Berntzen; Anne Pharo; Julie K Lindstad; Judith K Ludviksen; Ole-Lars Brekke; Andreas Barratt-Due; Erik Waage Nielsen; Christopher R Stokes; Terje Espevik; Inger Sandlie; Tom Eirik Mollnes
Journal:  J Immunol       Date:  2013-09-23       Impact factor: 5.422

Review 6.  Complement in immune and inflammatory disorders: therapeutic interventions.

Authors:  Daniel Ricklin; John D Lambris
Journal:  J Immunol       Date:  2013-04-15       Impact factor: 5.422

7.  The key roles of complement and tissue factor in Escherichia coli-induced coagulation in human whole blood.

Authors:  A Landsem; H Fure; D Christiansen; E W Nielsen; B Østerud; T E Mollnes; O L Brekke
Journal:  Clin Exp Immunol       Date:  2015-08-02       Impact factor: 4.330

8.  Cell-specific deletion of C1qa identifies microglia as the dominant source of C1q in mouse brain.

Authors:  Maria I Fonseca; Shu-Hui Chu; Michael X Hernandez; Melody J Fang; Lila Modarresi; Pooja Selvan; Grant R MacGregor; Andrea J Tenner
Journal:  J Neuroinflammation       Date:  2017-03-06       Impact factor: 8.322

9.  Ex vivo modelling of the formation of inflammatory platelet-leucocyte aggregates and their adhesion on endothelial cells, an early event in sepsis.

Authors:  Azzah Alharbi; Jonathan P Thompson; Nicholas P Brindle; Cordula M Stover
Journal:  Clin Exp Med       Date:  2018-09-06       Impact factor: 3.984

10.  Complement component 5 does not interfere with physiological hemostasis but is essential for Escherichia coli-induced coagulation accompanied by Toll-like receptor 4.

Authors:  A Landsem; H Fure; J Krey Ludviksen; D Christiansen; C Lau; M Mathisen; G Bergseth; S Nymo; K T Lappegård; T M Woodruff; T Espevik; T E Mollnes; O-L Brekke
Journal:  Clin Exp Immunol       Date:  2018-12-19       Impact factor: 4.330

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.